In:
Blood, American Society of Hematology, Vol. 123, No. 5 ( 2014-01-30), p. 632-639
Kurzfassung:
A high frequency of RAS/RAF mutations and recurrent mutations in PDGFRA and JAK3 were found in relapsed multiple myeloma patients. Patients with NRAS, but not KRAS, mutation exhibited significantly reduced sensitivity to bortezomib but not high-dose dexamethasone.
Materialart:
Online-Ressource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2013-05-504340
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2014
ZDB Id:
1468538-3
ZDB Id:
80069-7
Permalink